Presentation is loading. Please wait.

Presentation is loading. Please wait.

Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.

Similar presentations


Presentation on theme: "Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients."— Presentation transcript:

1 Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients by Betty Y. Chang, Michelle Francesco, Martin F. M. De Rooij, Padmaja Magadala, Susanne M. Steggerda, Min Mei Huang, Annemieke Kuil, Sarah E. M. Herman, Stella Chang, Steven T. Pals, Wyndham Wilson, Adrian Wiestner, Marcel Spaargaren, Joseph J. Buggy, and Laurence Elias Blood Volume 122(14): October 3, 2013 ©2013 by American Society of Hematology

2 Transient mobilization of lymphocytes in MCL patients treated with ibrutinib. Chang B Y et al. Blood 2013;122: ©2013 by American Society of Hematology

3 CD19+CD5+ cells have decreased CXCR4, CD38, and Ki67 expression following ibrutinib treatment. Chang B Y et al. Blood 2013;122: ©2013 by American Society of Hematology

4 Ibrutinib inhibits migration of MCL cells beneath stromal cells (pseudo-emperipoiesis) and the formation of CXCL12-stimulated cortical actin. Chang B Y et al. Blood 2013;122: ©2013 by American Society of Hematology

5 Ibrutinib suppresses BCR- and coculture-stimulated signaling and cytokine and chemokine production of MCL cells. Chang B Y et al. Blood 2013;122: ©2013 by American Society of Hematology

6 Ibrutinib inhibits BCR-activated adhesion of MCL cells. Chang B Y et al. Blood 2013;122: ©2013 by American Society of Hematology

7 Ibrutinib inhibits CXCL12-/CXCL13-activated adhesion and migration of MCL cells. Chang B Y et al. Blood 2013;122: ©2013 by American Society of Hematology

8 Ibrutinib inhibits BCR- and chemokine-induced adhesion of primary MCL cells. Chang B Y et al. Blood 2013;122: ©2013 by American Society of Hematology


Download ppt "Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients."

Similar presentations


Ads by Google